Tilray Q3 FY2025 Results: Shares Slump On 656% Wider Net Loss

Tilray Brands (TSX: TLRY) has reported its financial results for Q3 of fiscal 2025, ending February 28. The company’s net revenue stood at $185.8 million, inching down from $188.3 million in the same period last year.

On a constant-currency basis, net revenue reached approximately $193 million, but strategic initiatives and the discontinuation of certain low-margin SKUs weighed on overall sales. Notably, Tilray says it saw a $13 million shortfall resulting from SKU rationalization efforts.

In terms of gross profit, Tilray recorded $52.0 million, a 5% improvement over $49.4 million in last year’s third quarter. This gain yielded a gross margin of 28%, up from 26% a year ago.

Tilray’s cannabis segment generated $54.3 million in net revenue, down from $63.4 million in the prior-year period. Cannabis gross margins, however, rose to 41% from 33% last year. This notable margin expansion came partly from Tilray’s decision to redirect product from Canada to higher-margin international markets—though that strategy deferred some Canadian revenue from the third quarter into the forthcoming period.

The beverage segment reported net revenue of $55.9 million, up from $54.7 million last year, despite a $6 million reduction tied to SKU rationalization. Gross margin in this business also strengthened to 36%, compared to 34% in the third quarter of fiscal 2024. Tilray’s wellness division, which includes Manitoba Harvest, posted a modest year-over-year revenue increase to $14.1 million from $13.4 million, while pushing gross margins up to 32% from 30%.

Despite currency headwinds, Tilray’s distribution business saw net revenue of $61.5 million, an 8% year-over-year rise that becomes a 15% increase when viewed on a constant-currency basis. Gross margin edged down to 9% from 10% previously.

The most striking figure, however, was the net loss of $793.5 million, which dwarfed the prior year’s loss of $105.0 million. Management attributed roughly $700 million of that loss to non-cash impairment charges, driven by broader macroeconomic challenges and a decline in market capitalization.

Adjusted net loss was $2.9 million, down from an adjusted net income of $0.9 million a year ago, and adjusted EBITDA came in at $9.0 million compared to $10.2 million in the same quarter of fiscal 2024.

A key focus for management this quarter was fortifying the balance sheet. Tilray reduced total debt by $71 million, including a $58 million reduction in convertible notes, which helped bring the company’s net debt to trailing 12-month EBITDA below 1.0x. Tilray also ended the quarter with $248 million in cash and marketable securities.

Tilray revised its fiscal year 2025 net revenue guidance to a range of $850 million–$900 million, reflecting updated currency assumptions and the financial impact of SKU rationalizations. The company indicated that without the combined $50 million impact from currency and SKU discontinuations, net revenue would likely have landed in the $900 million–$950 million range.


Information for this story was found via the sources and companies mentioned. The author has no securities or affiliations related to the organizations discussed. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Soma Gold: Q3 Earnings Impacted By Labour Strike

Thesis Gold: The Multi-Billion Dollar Lawyers-Ranch PFS

Why Canada Has So Few Projects That Can Be Built Before 2030 | Dan Wilton – First Mining

Recommended

Northern Superior Shareholders Set To Receive Shares Of ONGold Resources Friday

Goliath Resources Sees Rob McEwen Increase Ownership Interest

Related News

TIlray: Canaccord Resumes Coverage Following Aphria Transaction

Earlier this week, Tilray (NASDAQ: TLRY) finalized their merger with Aphria (NASDAQ: APHA) (TSX: APHA),...

Saturday, May 8, 2021, 04:20:00 PM

Tilray: Canaccord Cuts Price Target To $12 After Q1 Results

On October 7, Tilray Inc (TSX: TLRY) reported their first quarter financial results for the...

Tuesday, October 12, 2021, 10:17:00 AM

More Than 80% of Canada’s Cannabis CEOs at the Time of Adult-Use Legalization Have Left

Three years into adult-use legalization – fewer than 1 in 5 CEOs who were there...

Sunday, October 24, 2021, 09:00:00 AM

Tilray Selected To Supply Medical Cannabis For French Experimental Program

Tilray Inc (NASDAQ: TLRY) has expanded its international operations to now include France. The company...

Tuesday, January 26, 2021, 07:55:19 AM

Tilray: Haywood Slashes Price Target From $7.25 To $4.00

Tilray Brands (TSX: TLRY) is expected to report its fiscal fourth-quarter results on July 26th....

Wednesday, July 13, 2022, 02:54:00 PM